Some of the best opportunities heading into 2026 may come from stocks that already hold strong market positions but are ...

Looking at options history for Merck & Co (NYSE: MRK) we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish ...

Schwab U.S. Dividend Equity ETF (SCHD) stands out for its much lower fees and higher yield, while ProShares - S&P 500 Dividend Aristocrats ETF (NOBL) features a more concentrated sector mix and ...

Thursday, December 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA ...

While acknowledging that Keytruda’s loss of exclusivity in 2028 represents the largest patent cliff in biopharma, BMO said it is now confident Merck can replace about 90% of peak Keytruda sales over ...

Antipodes Healthcare Portfolio Manager, Nick Cameron highlighted why Antipodes believes Merck & Co is entering 2026 at an ...

Investors with a lot of money to spend have taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection.

Halozyme HALO3.44%increase; green up pointing triangle was granted a preliminary injunction that would prevent Merck MRK 0.40%increase; green up pointing triangle & Co. from distributing a formulation ...

Merck MRK-1.98%decrease; red down pointing triangle & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics CDTX-0.02%decrease; red down pointing triangle in a move that ...